Friday, October 24, 2014

Aurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area.

What is Voclosporin?

Voclosporin is a novel calcineurin inhibitor and was engineered to be very effective, while minimizing the safety and side effect issues that are drawbacks of existing drugs in this class.

While other available calcineurin inhibitors (CNis), cyclosporine and tacrolimus, are effective in preventing rejection and may have utility in the treatment of LN, each has safety and side effect issues that can often be very serious and therefore restrict their clinical utility.  These side effects may include headache, nausea, diarrhea, high blood pressure, tremors, electrolyte disturbances, cosmetic changes, kidney toxicity and glucose intolerance.

We believe that voclosporin has important advantages over both cyclosporine and tacrolimus, and this has been borne out in clinical testing of over 2,000 patients conducted in various trials to date. 

Home   |   About Aurinia   |   Our Team   |   Products In Development   |   For Investors   |   Partnerships   |   Contact
Copyright 2013 by Aurinia Pharmaceuticals Inc.